Wall Street analysts expect Abbott Laboratories (NYSE:ABT) to post earnings of $0.73 per share for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Abbott Laboratories’ earnings. The highest EPS estimate is $0.74 and the lowest is $0.72. Abbott Laboratories posted earnings per share of $0.65 in the same quarter last year, which would indicate a positive year-over-year growth rate of 12.3%. The company is scheduled to announce its next quarterly earnings results on Wednesday, January 24th.

On average, analysts expect that Abbott Laboratories will report full year earnings of $2.50 per share for the current year, with EPS estimates ranging from $2.47 to $2.52. For the next fiscal year, analysts anticipate that the business will report earnings of $2.83 per share, with EPS estimates ranging from $2.80 to $2.85. Zacks’ EPS calculations are an average based on a survey of sell-side analysts that cover Abbott Laboratories.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Wednesday, October 18th. The healthcare product maker reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.01. The company had revenue of $6.83 billion for the quarter, compared to the consensus estimate of $6.72 billion. During the same quarter in the previous year, the business earned $0.59 earnings per share. Abbott Laboratories’s revenue was up 28.8% compared to the same quarter last year.

ABT has been the topic of a number of analyst reports. Royal Bank Of Canada reaffirmed a “buy” rating and set a $55.00 target price on shares of Abbott Laboratories in a research note on Tuesday, October 3rd. Jefferies Group LLC reaffirmed a “buy” rating and set a $58.00 target price on shares of Abbott Laboratories in a research note on Thursday, June 29th. TheStreet raised Abbott Laboratories from a “c+” rating to a “b” rating in a research note on Monday, July 3rd. Wells Fargo & Company reaffirmed an “outperform” rating and set a $54.00 target price (up previously from $47.50) on shares of Abbott Laboratories in a research note on Friday, June 30th. Finally, Cowen and Company reaffirmed an “outperform” rating and set a $55.00 target price (up previously from $48.00) on shares of Abbott Laboratories in a research note on Friday, July 14th. Seven investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $56.81.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/23/0-73-eps-expected-for-abbott-laboratories-abt-this-quarter.html.

In other news, insider Hubert L. Allen sold 4,600 shares of the stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $50.79, for a total transaction of $233,634.00. Following the completion of the sale, the insider now owns 105,479 shares in the company, valued at approximately $5,357,278.41. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Sharon J. Bracken sold 2,000 shares of the stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $49.16, for a total value of $98,320.00. Following the sale, the insider now owns 28,806 shares of the company’s stock, valued at approximately $1,416,102.96. The disclosure for this sale can be found here. In the last quarter, insiders have sold 333,310 shares of company stock valued at $16,857,255. Company insiders own 0.76% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the company. Villere ST Denis J & Co. LLC lifted its holdings in shares of Abbott Laboratories by 2.3% during the 2nd quarter. Villere ST Denis J & Co. LLC now owns 268,200 shares of the healthcare product maker’s stock valued at $13,037,000 after purchasing an additional 5,950 shares during the last quarter. Private Bank & Trust Co. lifted its holdings in shares of Abbott Laboratories by 12.3% during the 2nd quarter. Private Bank & Trust Co. now owns 30,322 shares of the healthcare product maker’s stock valued at $1,473,000 after purchasing an additional 3,330 shares during the last quarter. Comerica Securities Inc. purchased a new stake in shares of Abbott Laboratories during the 1st quarter valued at $2,833,000. Century Capital Management LLC purchased a new stake in shares of Abbott Laboratories during the 1st quarter valued at $4,332,000. Finally, AQR Capital Management LLC lifted its holdings in shares of Abbott Laboratories by 264.8% during the 1st quarter. AQR Capital Management LLC now owns 634,391 shares of the healthcare product maker’s stock valued at $28,173,000 after purchasing an additional 460,477 shares during the last quarter. Hedge funds and other institutional investors own 71.45% of the company’s stock.

Abbott Laboratories (ABT) traded down 0.43% during midday trading on Monday, reaching $56.08. The company’s stock had a trading volume of 4,709,045 shares. The firm has a market cap of $97.44 billion, a price-to-earnings ratio of 78.54 and a beta of 1.06. Abbott Laboratories has a 12-month low of $37.38 and a 12-month high of $56.69. The company’s 50-day moving average is $53.27 and its 200 day moving average is $48.51.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, November 15th. Shareholders of record on Friday, October 13th will be issued a dividend of $0.265 per share. The ex-dividend date of this dividend is Thursday, October 12th. This represents a $1.06 dividend on an annualized basis and a yield of 1.89%. Abbott Laboratories’s dividend payout ratio is currently 83.47%.

About Abbott Laboratories

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Get a free copy of the Zacks research report on Abbott Laboratories (ABT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.